Evidence map›Paper›PMID 40444741›Full record

ArticleInternational journal of cancer2025

Germline pathogenic variants in HIC1 DNA binding domains are associated with familial serrated polyposis syndrome.

Xavier Domínguez-Rovira, Coral Arnau-Collell, Gemma Gonfaus-Ortiz, Gemma Llargués-Sistac, Jenifer Muñoz, Ainara Llopis, Yasmin Soares de Lima, Cristina Herrera-Pariente, Leticia Moreira, Teresa Ocaña and 15 more

Abstract read
In one paragraph

Article in International journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Xavier Domínguez-RoviraGastroenterology, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), CIBEREHD, Hospital Clínic Barcelona, Barcelona, Spain.
Coral Arnau-CollellGastroenterology, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), CIBEREHD, Hospital Clínic Barcelona, Barcelona, Spain.
Gemma Gonfaus-OrtizGastroenterology, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), CIBEREHD, Hospital Clínic Barcelona, Barcelona, Spain.
Gemma Llargués-SistacGastroenterology, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), CIBEREHD, Hospital Clínic Barcelona, Barcelona, Spain.
Jenifer MuñozGastroenterology, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), CIBEREHD, Hospital Clínic Barcelona, Barcelona, Spain.
Ainara LlopisGastroenterology, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), CIBEREHD, Hospital Clínic Barcelona, Barcelona, Spain.
Yasmin Soares de LimaGastroenterology, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), CIBEREHD, Hospital Clínic Barcelona, Barcelona, Spain.
Cristina Herrera-ParienteGastroenterology, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), CIBEREHD, Hospital Clínic Barcelona, Barcelona, Spain.
Leticia MoreiraGastroenterology, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), CIBEREHD, Hospital Clínic Barcelona, Barcelona, Spain.
Teresa OcañaGastroenterology, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), CIBEREHD, Hospital Clínic Barcelona, Barcelona, Spain.
Marcos Díaz-GayDepartment of Cellular and Molecular Medicine, UC San Diego, La Jolla, California, USA.
Miriam CuatrecasasDepartment of Pathology, Hospital Clínic Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), CIBEREHD, Faculty of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Spain.
Sabela CarballalGastroenterology, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), CIBEREHD, Hospital Clínic Barcelona, Barcelona, Spain.
Anael López-NovoGalician Public Foundation of Genomic Medicine (FPGMX), Foundation Health Research Institute of Santiago de Compostela, Genomic Medicine Group, University of Santiago de Compostela, Santiago de Compostela, Spain.
Guerau FernàndezHospital Sant Joan de Déu, CIBERER, Barcelona, Spain.
Antoni CastellsGastroenterology, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), CIBEREHD, Hospital Clínic Barcelona, Barcelona, Spain.
Luis BujandaGastroenterology, Biogipuzkoa Health Research Institute, CIBEREHD. University of the Basque Country (UPV/EHU), San Sebastián, Spain.
Gabriel CapellàHereditary Cancer Program, Catalan Institute of Oncology, Oncobell Program, IDIBELL, CIBERONC, Barcelona, Spain.
Joaquín CubiellaDepartment of Gastroenterology, Ourense Hospital, CIBEREHD, Ourense, Spain.ORCID 0000-0002-9994-4831
Daniel Rodríguez-AlcaldeDigestive Diseases Section, Móstoles University Hospital, Madrid, Spain.
Laura ValleHereditary Cancer Program, Catalan Institute of Oncology, Oncobell Program, IDIBELL, CIBERONC, Barcelona, Spain.ORCID 0000-0003-0371-0844
Francesc BalaguerGastroenterology, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), CIBEREHD, Hospital Clínic Barcelona, Barcelona, Spain.
Clara Ruiz-PonteGalician Public Foundation of Genomic Medicine (FPGMX), Foundation Health Research Institute of Santiago de Compostela, Genomic Medicine Group, University of Santiago de Compostela, Santiago de Compostela, Spain.
Laia BonjochGastroenterology, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), CIBEREHD, Hospital Clínic Barcelona, Barcelona, Spain.
Sergi Castellví-BelGastroenterology, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), CIBEREHD, Hospital Clínic Barcelona, Barcelona, Spain.ORCID 0000-0003-1217-5097

Funding

Fundació la Marató de TV3 202008-10Fundación Científica Asociación Española Contra el Cáncer PRYGN211085CASTGeneralitat de Catalunya (CERCA) 2021 SGR 00716Generalitat de Catalunya (CERCA) 2021 SGR 01112Generalitat de Catalunya (CERCA) 2021 SGR 01185Generalitat de Catalunya (CERCA) AGAUR 2018FI_B1_00213HORIZON EUROPE Framework Programme, STEPUPIORS, COST Action TRANSCOLONCAN 101079217Instituto de Salud Carlos III 20/00113Instituto de Salud Carlos III 20/00226Instituto de Salud Carlos III 23/00189Instituto de Salud Carlos III CIBEREHD (CB06/04/0016)Instituto de Salud Carlos III CIBERONC (CB16/12/00234)'la Caixa' Foundation Program of Traslational Research in Cancer -IDIBAP INPHiNIT 100010434Ministerio de Ciencia e Innovación PID2020-112595RB-I00
6 · The paper itself

Abstract

Serrated polyposis syndrome (SPS) is characterized by multiple and/or large serrated polyps and increased colorectal cancer (CRC) risk. Germline predisposition to SPS is mostly undetermined. We aimed to identify a new inherited SPS predisposition component by functionally evaluating a candidate gene replicated in two independent SPS cohorts. Exome sequencing was performed in a discovery cohort of 39 patients from 16 SPS families, and validation of relevant results was performed by multi-gene panel sequencing in 211 independent SPS patients. Considering the discovery and validation cohorts, three predicted pathogenic missense variants were identified in HIC1 (Hypermethylated in cancer 1): c.110C>T (p.Ala37Val), c.1295A>G (p.Gln432Arg), and c.1411G>A (p.Gly471Arg). HIC1 is a tumor suppressor gene which encodes a transcriptional repressor involved in the DNA damage response, and it is commonly silenced in several cancers and serrated polyps. Two cellular models for HIC1, a CRISPR/Cas9 knockout model and an overexpression model, were produced. In these in vitro models, we assessed DNA damage levels and the SIRT1 regulatory pathway in the presence and absence of the identified variants. Compared to HIC1 wild-type, models harboring the HIC1 variants identified in SPS patients showed higher p-H2AX levels (marker of DNA damage) and impaired HIC1 binding to the SIRT1 promoter. Our results indicate that HIC1 genetic variants located in the zinc finger region affected its transcriptional repressor role. We can conclude that HIC1 may be involved in germline predisposition to SPS through an alteration of its repressor capacity and a faulty DNA damage response, as a molecular mechanism.

Indexed as

Adenomatous Polyposis ColiGerm-Line MutationKruppel-Like Transcription FactorsAdultColorectal NeoplasmsExome SequencingFemaleGenetic Predisposition to DiseaseHumansMaleMiddle AgedPedigreeSirtuin 1HIC1 protein, humanKruppel-Like Transcription FactorsSIRT1 protein, humanSirtuin 1colorectal cancerDNA damagefunctional studiesgermline predisposition to diseaseserrated polyposis syndrome

Identifiers

PMID40444741
PMCPMC12280854

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.